Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies
Authors
Keywords
-
Journal
JOURNAL OF HUMAN GENETICS
Volume 58, Issue 6, Pages 327-333
Publisher
Springer Nature
Online
2013-05-09
DOI
10.1038/jhg.2013.39
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of CYP2D6 Polymorphisms on Tamoxifen Responses of Women with Breast Cancer: A Microarray-based Study in Thailand
- (2013) Chonlaphat Sukasem et al. Asian Pacific Journal of Cancer Prevention
- Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy
- (2012) Solai Elango Damodaran et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
- (2012) M. P. Goetz et al. CLINICAL CANCER RESEARCH
- Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters
- (2012) Hiltrud Brauch et al. JOURNAL OF CLINICAL ONCOLOGY
- Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial and Re: CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) P. D. P. Pharoah et al. JNCI-Journal of the National Cancer Institute
- Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Y. Nakamura et al. JNCI-Journal of the National Cancer Institute
- Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) V. Stanton JNCI-Journal of the National Cancer Institute
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) James M. Rae et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Meredith M. Regan et al. JNCI-Journal of the National Cancer Institute
- The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1
- (2011) L. K. Teh et al. AAPS Journal
- Biological mechanisms and clinical implications of endocrine resistance in breast cancer
- (2011) Mario Giuliano et al. BREAST
- Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients
- (2011) Kazuma Kiyotani et al. BREAST CANCER RESEARCH AND TREATMENT
- Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment
- (2011) In Hae Park et al. BREAST CANCER RESEARCH AND TREATMENT
- Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients
- (2011) Joanne S. L. Lim et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Increasing Tamoxifen Dose in Breast Cancer Patients Based on CYP2D6 Genotypes and Endoxifen Levels: Effect on Active Metabolite Isomers and the Antiestrogenic Activity Score
- (2011) M F Barginear et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
- (2011) T E Mürdter et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
- (2011) L Madlensky et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacogenomics of Tamoxifen: Roles of Drug Metabolizing Enzymes and Transporters
- (2011) Kazuma Kiyotani et al. Drug Metabolism and Pharmacokinetics
- A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese
- (2011) Kazuma Kiyotani et al. HUMAN MOLECULAR GENETICS
- Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study
- (2011) William J. Irvin et al. JOURNAL OF CLINICAL ONCOLOGY
- Association between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients with Tamoxifen Treatment
- (2011) Hyung Seok Park et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- P-Glycoprotein (ABCB1) Transports the Primary Active Tamoxifen Metabolites Endoxifen and 4-Hydroxytamoxifen and Restricts Their Brain Penetration
- (2011) D. Iusuf et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- SULT1A1,CYP2C19and disease-free survival in early breast cancer patients receiving tamoxifen
- (2011) Ann M Moyer et al. PHARMACOGENOMICS
- Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
- (2010) Jennifer Gjerde et al. BMC CANCER
- CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification
- (2010) W. Schroth et al. CLINICAL CANCER RESEARCH
- Endoxifen, the Active Metabolite of Tamoxifen, Is a Substrate of the Efflux Transporter P-Glycoprotein (Multidrug Resistance 1)
- (2010) W. A. Teft et al. DRUG METABOLISM AND DISPOSITION
- Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population
- (2010) Kazuma Kiyotani et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Reply to T. Lang et al
- (2010) Kazuma Kiyotani et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
- (2010) Kazuma Kiyotani et al. JOURNAL OF CLINICAL ONCOLOGY
- Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response
- (2010) Kazuma Kiyotani et al. Pharmacogenetics and Genomics
- CYP2C19*2polymorphism is associated with increased survival in breast cancer patients using tamoxifen
- (2010) Rikje Ruiter et al. PHARMACOGENOMICS
- The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users
- (2009) Monique J. Bijl et al. BREAST CANCER RESEARCH AND TREATMENT
- Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment
- (2009) T. Ramón y Cajal et al. BREAST CANCER RESEARCH AND TREATMENT
- Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen
- (2009) Masatsugu Okishiro et al. CANCER
- CYP2D6 Genotyping for Functional-Gene Dosage Analysis by Allele Copy Number Detection
- (2009) N. Hosono et al. CLINICAL CHEMISTRY
- Multidrug Resistance Through the Spectacle of P-Glycoprotein
- (2009) Katalin Goda et al. CURRENT CANCER DRUG TARGETS
- Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
- (2009) Werner Schroth JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment
- (2008) Y. Xu et al. ANNALS OF ONCOLOGY
- Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy
- (2008) Kazuma Kiyotani et al. CANCER SCIENCE
- Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients
- (2008) W. G. Newman et al. CLINICAL CANCER RESEARCH
- Cytochrome P450 2D6 and Homeobox 13/Interleukin-17B Receptor: Combining Inherited and Tumor Gene Markers for Prediction of Tamoxifen Resistance
- (2008) M. P. Goetz et al. CLINICAL CANCER RESEARCH
- Multiplex PCR-based real-time invader assay (mPCR-RETINA): a novel SNP-based method for detecting allelic asymmetries within copy number variation regions
- (2007) Naoya Hosono et al. HUMAN MUTATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search